Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: Short- and long-term outcomes

Olga Frankfurt*, Shuo Ma, Leo I Gordon, Jane Norma Winter, Jeanne M Horowitz, Alfred W Rademaker, Bing Bing Weitner, LoAnn Charlotte Peterson, Jessica K Altman, Martin S. Tallman, Adam Petrich, Steven T. Rosen

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Scopus citations


We investigated the safety, efficacy, and long-term outcomes of alemtuzumab and rituximab (AR) combination therapy in previously untreated patients with CLL. Thirty patients, ages 28-80 years, 47% older than 60 years, 90% Rai clinical stages II-IV, and 67% without favorable cytogenetics received AR. Based on the NCI-WG 1996 criteria, OR was 100%, with 60% CR. With CT scans OR was 70%, with 23% CR, 47% PR, and 30% SD. Sixty-seven percent of patients showed no evidence of MRD in the bone marrow by 6-color flow cytometry. Median PFS, TFS, and 5-year OS were 24.4, 50.7 months, and 80%, respectively. Grade 3/4 neutropenia and thrombocytopenia were reported in 30% and 7% of patients, respectively. CMV reactivation, asymptomatic in all but one patient, occurred in 8 patients. Immunotherapy with alemtuzumab and rituximab results in robust responses and long asymptomatic therapy-free intervals. It is well tolerated with infrequent, predictable, and easily managed complications.

Original languageEnglish (US)
Pages (from-to)315-323
Number of pages9
JournalLeukemia and Lymphoma
Issue number2
StatePublished - Feb 1 2015



  • Alemtuzumab
  • CLL
  • Immunotherapy
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this